查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1837515

獸用抗生素和抗菌藥物市場按類別、動物種類、給藥途徑、劑型和分銷管道分類－2025-2032年全球預測

Animal Antibiotics & Antimicrobials Market by Class, Animal Species, Administration Route, Formulation, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，獸用抗生素和抗菌藥物市場將成長至 10.2013 億美元，複合年成長率為 5.45%。

關鍵市場統計數據
基準年2024年 6.6723億美元
預計年份：2025年 7.0333億美元
預測年份 2032 10.2013億美元
複合年成長率 (%) 5.45%

簡明扼要地闡述抗菌藥物管理、科學進步和監管演變是塑造獸藥發展的基本力量。

獸用治療和抗菌藥物管理的發展呈現出科學創新、監管審查和不斷變化的商業性獎勵交織而成的複雜格局。本執行摘要概述了重塑動物抗生素和抗菌藥物使用格局的各種因素，重點闡述了抗菌藥物管理優先事項、供應鏈韌性和治療方法創新如何融合併重新定義行業實踐。引言部分組裝這些動態置於全球遏制抗菌素抗藥性努力的背景下進行分析，同時強調了保護動物健康、福利和生產力的持續必要性。

讀者將從中獲得一種整合的觀點，該視角將特定類別的治療討論與跨動物物種和給藥途徑的實際考慮聯繫起來。透過將近期監管里程碑和貿易政策發展與製劑和診斷支援方面的技術進步並置，本部分旨在幫助相關人員了解將影響中期規劃的直接營運影響和策略曲折點。其目的是在深入探討詳細的市場區隔、區域差異、企業行動和實證建議之前，為領導者提供簡明扼要的概覽。

診斷、管理政策和供應鏈數位化將如何重新定義治療策略和市場准入

一場產業變革正在進行，科學、監管、商業和物流等多個因素相互交織，共同塑造獸用抗生素和抗菌藥物的新營運標準。診斷能力的提升和對標靶治療日益重視，正在減少對廣譜經驗性治療的依賴；同時，對新型製劑和給藥方法的投資，使得更精準的給藥和更低的殘留成為可能。同時，政策制定者和獸醫監管機構正在加強監管，並推廣強調合理使用、監測和可追溯性的管理框架。這些發展趨勢促使生產者優先考慮那些既能證明療效又能符合管理期望的產品系列。

在商業方面，供應鏈重組和數位化正在改變產品到達終端用戶的方式。可追溯系統和電子處方箋平台的興起有助於遵守處方規定，同時製造商和經銷商也在探索附加價值服務，例如診斷支援、數據分析和基本契約。此外，免疫調節劑、益生菌和精準營養等替代療法的出現，也對傳統抗生素構成了競爭壓力。這些轉變並非漸進式的，而是結構性的重新調整，要求企業重新思考其產品開發、打入市場策略和顧客關係模式。

評估2025年關稅調整對動物保健產品價值鏈的採購、生產分配和商業性定位的影響。

美國2025年實施的新關稅和貿易措施，增加了貿易主導的複雜性，影響了採購、生產決策和雙邊供應關係。關稅調整影響了進口中間體和成品製劑的相對競爭力，迫使一些製造商重新評估籌資策略，檢驗經銷商和飼料廠也必須調整其採購週期和庫存管理，以降低成本波動，並維持對獸醫和畜牧生產者的持續供應。

這給批發商和經銷商層面的定價帶來了壓力，進而影響到下游流程，例如治療方法的選擇和給藥途徑的決策。例如，如果注射劑的物流成本增加，能夠整合到水溶性或飼料基給藥系統中的產品可能具有競爭優勢。同時，擁有多元化配方能力和靈活生產佈局的公司更有能力應對關稅帶來的成本變化，而不會影響服務水準。因此，關稅的累積影響不僅限於直接的成本增加，還會促使整個價值鏈在採購、生產分配和商業性定位方面進行策略調整。

將治療層級、物種特異性用途、給藥途徑、製劑和通路等因素與策略意義連結起來，進行整合細分洞察。

細分市場分析揭示了每種治療層級、動物種類、給藥途徑、製劑和通路的不同促進因素和商業性槓桿，每種情況都需要不同的策略應對措施。在考慮治療層級時，相關人員應考慮從Aminoglycosides到四環黴素頻譜（包括慶大霉素、新黴素和Aminoglycosides等亞類成分）；BETA-內醯胺類（包括頭孢菌素和青黴素）；Fluoroquinolones（包括Ciprofloxacin、恩諾沙星和馬波沙星）；大環內酯類（包括紅黴素、螺旋黴素、替米考星和泰樂菌素）；磺胺類藥物（包括磺胺二甲嘧啶和磺胺二甲嘧啶）；以及四環黴素（包括四環黴素、多西環素、四環黴素和四環黴素）。這些分類會影響監管風險狀況、盡職調查以及配方調整的技術障礙。

從動物種類來看，水產養殖、牛、伴侶動物、家禽和豬的需求模式和用藥方式差異顯著，每種動物都有其獨特的飼養管理方式、治療網路基地台以及對藥物殘留和停藥反應的敏感性。飼料添加劑和水溶液仍然是牛層面干涉的重要手段，注射劑是靶向全身治療的首選，口服和局部製劑則針對特定的臨床情況，而體外給藥雖然應用範圍有限，但卻是家禽早期療育的重要方法。不同的製劑類型——Bolus、液體、粉末和預混合料——對生產、穩定性和劑量控制提出了不同的挑戰，進而影響保存期限和易用性。飼料廠負責一體化生產系統，藥房和獸醫診所提供特殊製劑，而線上管道則為伴侶飼主和小農戶提供了更多便利。整合這些細分維度有助於更細緻地進行產品組合優先排序、監管規劃和商業性決策，從而更好地適應每個終端使用者群體的實際運作。

在全球範圍內，區域監管差異、生產體系和供應鏈佈局如何驅動差異化的需求和打入市場策略？

區域性因素正在塑造產品需求模式、監管執法和供應策略，因此需要根據地理情況做出相應的應對。在美洲，監管現代化和對數據主導監管的重視正在推動對支持合規性和可追溯性的產品和服務的需求。歐洲、中東和非洲的監管環境複雜多樣，各地的監管政策不盡相同，進口依賴性造成了一定的脆弱性，而能夠實現殘留物監測和低溫運輸完整性的技術則蘊藏著巨大的發展機會。在這個複雜的區域，許多地方既有協調統一的努力，也有各國特有的規則，因此需要靈活的註冊和市場進入方式。

亞太地區的特點是獸醫實踐的快速現代化、水產養殖和家禽生產的持續大規模化，以及獸醫用品數位化工具和電子商務的日益普及。該地區的製造能力和供應鏈節點在全球採購中也發揮核心作用，監管機構在調整政策以適應當地疾病壓力的同時，也日益與國際標準接軌。總而言之，區域差異影響著在地化生產、通路夥伴關係以及設計符合當地基礎設施和監管要求的管理支援服務的優先事項。

製造商之間的競爭行為和策略要務，揭示了研發平台、服務捆綁和製造彈性如何決定市場差異化。

公司層面的動態反映了一系列策略姿態，從垂直整合的傳統企業到專業學名藥生產商，再到靈活的生物技術參與企業。大型生產商正投資於平台能力建設，以加快改良產品的上市速度並加強對監管要求的合規性；而規模較小的公司和契約製造則專注於以具有成本競爭力的方式生產小眾治療層級類別或飼料級產品。診斷服務提供者與治療藥物生產商之間的策略聯盟正成為一種關鍵模式，這種聯盟能夠提供結合治療藥物和決策支援工具的捆綁式解決方案，從而增強對獸醫和生產者的價值提案。

此外，商業性差異化日益依賴服務產品，例如獸醫教育、農場診斷和客製化給藥方案，以加深客戶關係並建立商品化障礙。供應鏈韌性和生產靈活性也正在成為核心競爭優勢，尤其對於那些能夠根據不斷變化的客戶需求和法規無縫調整製劑劑型（如Bolus、液體、粉劑和預混合料）的公司而言更是如此。最後，儘管智慧財產權和監管獨佔策略對於投資新型化合物和專有給藥系統的公司仍然至關重要，但商業化過程通常取決於療效、安全性和監管方面的充分驗證。

採取切實可行的跨職能行動，協調研發、監管參與和商業性策略，以增強管理、供應鏈韌性和市場應對力。

為了因應不斷變化的抗生素市場格局，行業領導者必須採取一套綜合措施，協調產品開發、監管溝通和商業性執行。企業應優先投資於診斷和改進給藥系統，以提高給藥準確性並降低抗藥性風險，同時拓展支持藥物管理文件和可追溯性的能力。此外，加強供應商多元化並探索區域生產方案，有助於緩解與貿易相關的成本壓力，並確保終端用戶服務的連續性。

在商業層面，企業應透過教育計畫、結果監測和配套服務，與獸醫和飼料管理人員建立緊密的夥伴關係，凸顯其產品在監管方面的高階定位。在營運層面，企業應統一不同配方產品的穩定性和持久性資料包，以加快監管互動並支持跨境註冊。最後，企業領導者必須建立跨職能的管治，整合監管前瞻性、開發平臺和商業計劃，確保產品組合決策既反映臨床效用，也反映系統層面的監管責任。

我們透明的調查方法結合了關鍵相關人員的參與、監管文件審查和結構化的分析框架，以確保獲得可操作和有效的見解。

本報告的調查方法結合了定性專家訪談、二手文獻綜述、監管文件審查以及結構化的相關人員諮詢，以確保得出可靠且可操作的研究結論。主要資訊來源包括與執業獸醫、生產經理、生產和分銷專家以及監管負責人的討論，以了解實踐現狀和新興趨勢。二手分析綜合了公開的監管文件、技術專題論文和同行評審文獻，以檢驗不同治療類別和動物物種的臨床、安全性和用藥管理方面的考慮因素。

本研究採用的分析框架包括：細分映射，用於將產品屬性與最終用戶需求相匹配；供應鏈韌性評估，用於評估採購和生產的靈活性；以及情境分析，用於了解應對政策和貿易變化的潛在措施。研究對不同資料來源進行了交叉檢驗，以協調不同觀點並對研究結果進行三角驗證。在適用情況下，研究還審查了監管時間表和指導文件，以評估合規負擔和註冊途徑。調查方法始終保持透明，以確保關鍵分析步驟的可重複性。

一份簡潔的綜合報告，重點闡述了管理協調、技術採納和在地化供應策略將如何決定未來的競爭地位。

總之，獸用抗生素和抗菌藥物市場受到日益成長的監管期望的限制，但同時也受益於技術和商業性創新，這些創新開闢了疾病預防和治療的新途徑。整合診斷工具、靈活製劑能力和符合監管要求的提案主張的相關人員將更有能力滿足監管要求和客戶期望。同時，區域差異和不斷變化的貿易政策凸顯了具有地域意識的採購和打入市場策略既能保障供應的連續性，又能滿足當地的合規要求。

最終，該行業的近期發展軌跡將取決於企業如何有效地將科學進步轉化為既具有臨床益處又符合管理規範的產品和服務。那些迅速行動，建立跨職能合作、投資提升生產韌性並與獸醫界建立務實夥伴關係關係的企業，將更有利於在日益嚴格的審查和快速變化的時代保持競爭力並創造差異化價值。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 在養豬業中，噬菌體療法作為一種標靶抗菌解決方案的應用日益增多。
  • 增加對新型胜肽類抗菌藥物的投資，以對抗畜牧業中的多重抗藥性病原體。
  • 實施抗菌藥物管理計劃，以最佳化酪農的抗生素使用模式
  • 在農場推廣快速診斷技術，以便早期發現動物感染疾病
  • 消費者對不含抗生素殘留肉類的需求不斷成長，推動了標籤透明度的提升。
  • 將精準獸醫學與數據分析結合，以客製化抗生素給藥方案
  • 開發免疫調節飼料添加劑以減少牛對傳統抗生素的依賴
  • 製藥公司與生技Start-Ups合作研發下一代抗生素

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按類別分類的動物抗生素和抗菌藥物市場

  • Aminoglycosides
    • 慶大霉素
    • 新黴素
    • 鏈黴素
  • BETA-內醯胺類
    • 頭孢菌素
    • 青黴素
  • Fluoroquinolones
    • Ciprofloxacin
    • 恩諾沙星
    • 馬波沙星
  • 大環內酯類
    • 紅黴素
    • 螺旋黴素
    • 替米考星
    • 泰樂菌素
  • 磺胺類藥物
    • 磺胺二甲氧嗪
    • 磺胺二甲嗪
  • 四環黴素
    • 四環黴素
    • 多西環素
    • 四環黴素
    • 四環黴素

9. 依動物種類分類的動物抗生素和抗菌藥物市場

  • 水產養殖
  • 牛
  • 伴侶動物
  • 家禽
  • 豬

第10章：依給藥途徑分類的動物抗生素和抗菌藥物市場

  • 飼料添加劑
  • 蛋的內部
  • 注射
  • 口服
  • 外用
  • 水溶性

第11章：以劑型分類的動物抗生素和抗菌劑市場

  • Bolus
  • 液體
  • 粉末
  • 預混合料

第12章：按分銷管道分類的動物抗生素和抗菌藥物市場

  • 飼料廠
  • 線上
  • 藥局
  • 獸醫診所

第13章：按地區分類的動物抗生素和抗菌劑市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 依類別分類的動物抗生素和抗菌劑市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國動物抗生素和抗菌藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • American Regent Inc.
    • Ayurvet
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • Ceva Sante Animale
    • Chanelle Pharma
    • Dechra Pharmaceuticals PLC
    • Eco Animal Health Group PLC
    • Elanco Animal Health Incorporated
    • Eli Lilly and Company
    • Endovac Animal Health, LLC
    • Hester Biosciences Limited
    • Hipra Laboratories, SA
    • Inovet Group
    • Neogen Corporation
    • Norbrook Laboratories Ltd.
    • Novartis AG
    • Phibro Animal Health Corporation
Product Code: MRR-031BF22F949D

The Animal Antibiotics & Antimicrobials Market is projected to grow by USD 1,020.13 million at a CAGR of 5.45% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 667.23 million
Estimated Year [2025] USD 703.33 million
Forecast Year [2032] USD 1,020.13 million
CAGR (%) 5.45%

A concise orientation that frames antimicrobial stewardship, scientific progress, and regulatory evolution as the foundational forces shaping animal therapeutics

The evolution of veterinary therapeutics and antimicrobial management presents a dense landscape of scientific innovation, regulatory scrutiny, and shifting commercial incentives. This executive summary synthesizes the drivers reshaping animal antibiotic and antimicrobial use, focusing on how stewardship priorities, supply chain resilience, and therapeutic innovation are converging to redefine industry practice. The introduction frames these dynamics against the backdrop of global efforts to curb antimicrobial resistance, while also recognizing the enduring need to protect animal health, welfare, and productivity.

Readers will find an integrated perspective that connects class-specific therapeutic discussions with practical considerations across animal species and administration routes. By situating recent regulatory milestones and trade policy developments alongside technological advances in formulation and diagnostic support, this section primes stakeholders to understand both immediate operational impacts and the strategic inflection points that will influence medium-term planning. The intent is to equip leaders with a concise orientation before delving into detailed segmentation, regional nuance, corporate behavior, and evidence-based recommendations.

How converging advancements in diagnostics, stewardship policy, and supply chain digitalization are redefining therapeutic strategy and market engagement

Industry transformation is underway as multiple vectors-scientific, regulatory, commercial, and logistical-intersect to produce new operating norms for animal antibiotics and antimicrobials. Advances in diagnostic capability and a growing emphasis on targeted therapy are reducing reliance on broad-spectrum empiric treatments, while investments in novel formulations and delivery methods are enabling more precise dosing and reduced residues. Concurrently, policy makers and veterinary authorities are tightening oversight and promoting stewardship frameworks that emphasize judicious use, surveillance, and traceability. These developments are prompting manufacturers to prioritize product portfolios that can demonstrate both efficacy and alignment with stewardship expectations.

On the commercial front, supply chain reconfiguration and digitalization are changing how products reach end users. Enhanced traceability systems and e-prescription platforms are facilitating adherence to prescribing rules, while manufacturers and distributors explore value-added services such as diagnostic support, data analytics, and outcome-based contracts. Moreover, the emergence of alternative approaches-such as immunomodulators, probiotics, and precision nutrition-introduces competitive pressure on traditional antibiotic classes. Taken together, these shifts are not incremental; they represent a structural reorientation that requires companies to rethink product development, market access strategies, and customer engagement models.

Assessment of how 2025 tariff adjustments have reshaped sourcing, production allocation, and commercial positioning across the animal therapeutics value chain

The introduction of new tariffs and trade measures in the United States in 2025 has added an overlay of trade-driven complexity that affects procurement, manufacturing decisions, and bilateral supply relationships. Tariff adjustments have influenced the relative competitiveness of imported intermediates and finished formulations, prompting some manufacturers to reassess sourcing strategies, validate alternative suppliers, and accelerate nearshoring or regionalization of production where feasible. In parallel, distributors and feed mills have had to adapt procurement cycles and inventory management to mitigate cost volatility and maintain continuity of supply for veterinarians and livestock operations.

Consequently, pricing dynamics at the wholesale and distributor level have experienced pressure, which in turn has implications for downstream decisions about therapeutic selection and administration routes. For example, products that can be integrated into water-soluble or feed-based delivery systems may gain operational advantages when logistical costs for injectable supplies rise. At the same time, firms with diversified formulation capabilities and flexible manufacturing footprints are better positioned to absorb tariff-induced cost shifts without disrupting service levels. The cumulative impact of the tariffs therefore extends beyond immediate cost increments; it is catalyzing strategic adjustments in sourcing, manufacturing allocation, and commercial positioning across the value chain.

Integrated segmentation insights that map therapeutic classes, species-specific use, administration routes, formulations, and distribution pathways to strategic implications

Segmentation analysis reveals differentiated drivers and commercial levers across therapeutic class, animal species, administration route, formulation, and distribution channel, each demanding distinct strategic responses. When examining therapeutic class, stakeholders must account for the spectrum from aminoglycosides to tetracyclines, with subcomponents such as gentamicin, neomycin, streptomycin among the aminoglycosides and cephalosporins and penicillins within the beta-lactams; fluoroquinolones include ciprofloxacin, enrofloxacin, and marbofloxacin; macrolides encompass erythromycin, spiramycin, tilmicosin, and tylosin; sulfonamides feature sulfadimethoxine and sulfamethazine; and tetracyclines include chlortetracycline, doxycycline, oxytetracycline, and tetracycline. These class distinctions influence regulatory risk profiles, stewardship scrutiny, and technical barriers to reformulation.

Turning to animal species, demand patterns and administration norms differ markedly among aquaculture, cattle, companion animals, poultry, and swine, each exhibiting unique husbandry practices, treatment access points, and sensitivity to residue and withdrawal concerns. Administration routes shape operational use cases: feed additives and water-soluble solutions remain important for herd-level interventions, injectables are preferred for targeted systemic therapy, oral and topical forms serve specific clinical contexts, and in ovo delivery is a niche yet critical approach for early-life interventions in poultry. Formulation types such as bolus, liquid, powder, and premix present different manufacturing, stability, and dosing challenges that affect shelf life and ease of use. Distribution channels create distinct pathways to end users: feed mills serve integrated production systems, pharmacies and veterinary clinics provide professional dispensing, and online channels are expanding access and convenience for companion animal owners and smallholders. Integrating these segmentation layers enables more nuanced portfolio prioritization, regulatory planning, and commercial articulation tailored to the operational realities of each end-user segment.

How regional regulatory nuance, production systems, and supply chain footprints are driving differentiated demand and market access strategies across global regions

Regional dynamics are shaping product demand patterns, regulatory enforcement, and supply strategies in ways that require geographically informed responses. In the Americas, regulatory modernization and emphasis on data-driven stewardship are driving demand for products and services that support compliance and traceability, while strong integrated beef and poultry industries create concentrated channels for feed-based and injectable therapeutics. Europe, Middle East & Africa present a heterogeneous regulatory landscape where stewardship policies vary by jurisdiction, import dependencies create vulnerabilities, and opportunities exist for technologies that enable residue monitoring and cold-chain integrity. In many parts of this combined region, harmonization efforts coexist with country-specific rules, necessitating flexible registration and market access approaches.

Asia-Pacific is characterized by rapid modernization of veterinary practice, persistent high volumes in aquaculture and poultry production, and growing adoption of digital tools and e-commerce for veterinary supplies. The region's manufacturing capacity and supply chain nodes also play a central role in global sourcing, and regulatory authorities are increasingly aligning with international standards while adapting policies to local disease pressures. Taken together, regional contrasts influence priorities for manufacturing localization, channel partnerships, and the design of stewardship-supporting services that are sensitive to local infrastructure and regulatory expectations.

Competitive behaviors and strategic imperatives among manufacturers revealing why R&D platforms, service bundling, and manufacturing flexibility determine market differentiation

Company-level dynamics reflect a spectrum of strategic postures, ranging from vertically integrated incumbents to specialized generics producers and agile biotechnology entrants. Leading manufacturers are investing in platform capabilities that reduce time-to-market for reformulated products and enhance compliance with stewardship requirements, while smaller firms and contract manufacturers focus on niche therapeutic classes or cost-competitive production for feed-grade products. Strategic partnerships between diagnostic providers and therapeutic manufacturers are emerging as a key pattern, enabling bundled solutions that combine treatment with decision-support tools and thereby strengthen value propositions to veterinarians and producers.

In addition, commercial differentiation increasingly leverages service offerings such as veterinary education, on-farm diagnostics, and tailored dosing protocols to deepen customer relationships and create barriers to commoditization. Supply chain resilience and manufacturing flexibility are also rising as core competitive advantages, particularly for companies that can pivot between bolus, liquid, powder, and premix formats in response to customer needs or regulatory shifts. Finally, intellectual property and regulatory exclusivity strategies remain important for firms investing in novel compounds or proprietary delivery systems, though the timeline to commercialization often depends on the ability to demonstrate robust safety and stewardship-aligned efficacy.

Practical, cross-functional actions that align R&D, regulatory engagement, and commercial tactics to strengthen stewardship, supply resilience, and market responsiveness

Industry leaders must adopt an integrated set of actions that align product development, regulatory engagement, and commercial execution to navigate the evolving antimicrobial landscape. Companies should prioritize investments in diagnostic-linked therapies and reformulated delivery systems that improve dosing precision and reduce the likelihood of resistance development, while simultaneously expanding capabilities to support stewardship documentation and traceability. At the same time, strengthening supplier diversification and considering regional manufacturing options can mitigate trade-related cost pressures and maintain service continuity for end users.

On the commercial side, organizations should build closer partnerships with veterinarians and feed managers through education programs, outcome monitoring, and bundled service offerings that justify premium positioning for stewardship-compatible products. Operationally, firms should standardize stability and residue data packages across formulation types to speed regulatory interactions and support cross-border registrations. Finally, corporate leaders must foster cross-functional governance that integrates regulatory foresight, R&D pipelines, and commercial planning so that portfolio decisions reflect both clinical utility and system-level stewardship responsibilities.

A transparent methodology blending primary stakeholder engagement, regulatory dossier review, and structured analytical frameworks to ensure actionable and validated insights

The research methodology underpinning the report combines qualitative expert interviews, secondary literature synthesis, regulatory dossier review, and structured stakeholder consultations to ensure robust and actionable findings. Primary inputs include discussions with practicing veterinarians, production managers, manufacturing and distribution specialists, and regulatory affairs professionals to capture operational realities and emergent trends. Secondary analysis synthesizes publicly available regulatory documents, technical monographs, and peer-reviewed literature to validate clinical, safety, and stewardship considerations across therapeutic classes and species.

Analytical frameworks used in the study include segmentation mapping to align product attributes with end-user needs, supply chain resilience assessment to evaluate sourcing and manufacturing flexibilities, and scenario analysis to understand potential responses to policy and trade shifts. Cross-validation procedures were applied across data sources to reconcile divergent viewpoints and to triangulate findings. Where applicable, regulatory timelines and guidance documents were reviewed to assess compliance burdens and registration pathways, and methodological transparency was maintained throughout to support reproducibility of the core analytical steps.

A succinct synthesis emphasizing how stewardship alignment, technological adoption, and regionalized supply strategies jointly determine future competitive positioning

In conclusion, the animal antibiotics and antimicrobials landscape is simultaneously constrained by rising stewardship expectations and energized by technological and commercial innovations that open alternative pathways to disease prevention and treatment. Stakeholders who integrate diagnostic tools, flexible formulation capabilities, and stewardship-aligned value propositions will be better equipped to meet regulatory demands and customer expectations. Meanwhile, regional differences and trade policy developments underscore the importance of geographically aware sourcing and market entry strategies that protect supply continuity while meeting local compliance requirements.

Ultimately, the sector's near-term trajectory will be shaped by how effectively companies translate scientific advances into products and services that demonstrate both clinical benefit and stewardship compatibility. Organizations that move quickly to build cross-functional alignment, invest in manufacturing resiliency, and forge practical partnerships with the veterinary community will be best positioned to sustain relevance and create differentiated value in an era of heightened scrutiny and rapid change.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing adoption of bacteriophage therapy as targeted antimicrobial solution in swine operations
  • 5.2. Rising investment in novel peptide based antimicrobials to combat multidrug resistant pathogens in livestock
  • 5.3. Implementation of antimicrobial stewardship programs across dairy farms to optimize antibiotic usage patterns
  • 5.4. Expansion of rapid on farm diagnostic technologies for early detection of animal infectious diseases
  • 5.5. Increasing consumer demand for antibiotic residue free meat driving label transparency initiatives
  • 5.6. Integration of precision veterinary medicine using data analytics to tailor antimicrobial dosing regimens
  • 5.7. Developments in immunomodulatory feed additives to reduce reliance on traditional antibiotics in cattle
  • 5.8. Collaborations between pharmaceutical companies and biotech startups for next generation antimicrobial research

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Antibiotics & Antimicrobials Market, by Class

  • 8.1. Aminoglycosides
    • 8.1.1. Gentamicin
    • 8.1.2. Neomycin
    • 8.1.3. Streptomycin
  • 8.2. Beta Lactams
    • 8.2.1. Cephalosporins
    • 8.2.2. Penicillins
  • 8.3. Fluoroquinolones
    • 8.3.1. Ciprofloxacin
    • 8.3.2. Enrofloxacin
    • 8.3.3. Marbofloxacin
  • 8.4. Macrolides
    • 8.4.1. Erythromycin
    • 8.4.2. Spiramycin
    • 8.4.3. Tilmicosin
    • 8.4.4. Tylosin
  • 8.5. Sulfonamides
    • 8.5.1. Sulfadimethoxine
    • 8.5.2. Sulfamethazine
  • 8.6. Tetracyclines
    • 8.6.1. Chlortetracycline
    • 8.6.2. Doxycycline
    • 8.6.3. Oxytetracycline
    • 8.6.4. Tetracycline

9. Animal Antibiotics & Antimicrobials Market, by Animal Species

  • 9.1. Aquaculture
  • 9.2. Cattle
  • 9.3. Companion Animals
  • 9.4. Poultry
  • 9.5. Swine

10. Animal Antibiotics & Antimicrobials Market, by Administration Route

  • 10.1. Feed Additives
  • 10.2. In Ovo
  • 10.3. Injectable
  • 10.4. Oral
  • 10.5. Topical
  • 10.6. Water Soluble

11. Animal Antibiotics & Antimicrobials Market, by Formulation

  • 11.1. Bolus
  • 11.2. Liquid
  • 11.3. Powder
  • 11.4. Premix

12. Animal Antibiotics & Antimicrobials Market, by Distribution Channel

  • 12.1. Feed Mills
  • 12.2. Online
  • 12.3. Pharmacies
  • 12.4. Veterinary Clinics

13. Animal Antibiotics & Antimicrobials Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Animal Antibiotics & Antimicrobials Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Animal Antibiotics & Antimicrobials Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. American Regent Inc.
    • 16.3.2. Ayurvet
    • 16.3.3. Bayer AG
    • 16.3.4. Boehringer Ingelheim GmbH
    • 16.3.5. Ceva Sante Animale
    • 16.3.6. Chanelle Pharma
    • 16.3.7. Dechra Pharmaceuticals PLC
    • 16.3.8. Eco Animal Health Group PLC
    • 16.3.9. Elanco Animal Health Incorporated
    • 16.3.10. Eli Lilly and Company
    • 16.3.11. Endovac Animal Health, LLC
    • 16.3.12. Hester Biosciences Limited
    • 16.3.13. Hipra Laboratories, S.A.
    • 16.3.14. Inovet Group
    • 16.3.15. Neogen Corporation
    • 16.3.16. Norbrook Laboratories Ltd.
    • 16.3.17. Novartis AG
    • 16.3.18. Phibro Animal Health Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ANIMAL SPECIES, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ANIMAL SPECIES, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY GENTAMICIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY GENTAMICIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY GENTAMICIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY GENTAMICIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY GENTAMICIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY GENTAMICIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY NEOMYCIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY NEOMYCIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY NEOMYCIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY NEOMYCIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY NEOMYCIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY NEOMYCIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY STREPTOMYCIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY STREPTOMYCIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY STREPTOMYCIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY STREPTOMYCIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY STREPTOMYCIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY STREPTOMYCIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PENICILLINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PENICILLINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CIPROFLOXACIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CIPROFLOXACIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CIPROFLOXACIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CIPROFLOXACIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CIPROFLOXACIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CIPROFLOXACIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ENROFLOXACIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ENROFLOXACIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ENROFLOXACIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ENROFLOXACIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ENROFLOXACIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ENROFLOXACIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MARBOFLOXACIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MARBOFLOXACIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MARBOFLOXACIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MARBOFLOXACIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MARBOFLOXACIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MARBOFLOXACIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ERYTHROMYCIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ERYTHROMYCIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ERYTHROMYCIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ERYTHROMYCIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ERYTHROMYCIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ERYTHROMYCIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SPIRAMYCIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SPIRAMYCIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SPIRAMYCIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SPIRAMYCIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SPIRAMYCIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SPIRAMYCIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TILMICOSIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TILMICOSIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TILMICOSIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TILMICOSIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TILMICOSIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TILMICOSIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TYLOSIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TYLOSIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TYLOSIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TYLOSIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TYLOSIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TYLOSIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFADIMETHOXINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFADIMETHOXINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFADIMETHOXINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFADIMETHOXINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFADIMETHOXINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFADIMETHOXINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFAMETHAZINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFAMETHAZINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFAMETHAZINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFAMETHAZINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFAMETHAZINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFAMETHAZINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CHLORTETRACYCLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CHLORTETRACYCLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CHLORTETRACYCLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CHLORTETRACYCLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CHLORTETRACYCLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CHLORTETRACYCLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DOXYCYCLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DOXYCYCLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DOXYCYCLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DOXYCYCLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DOXYCYCLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DOXYCYCLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY OXYTETRACYCLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY OXYTETRACYCLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY OXYTETRACYCLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY OXYTETRACYCLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY OXYTETRACYCLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY OXYTETRACYCLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ANIMAL SPECIES, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ANIMAL SPECIES, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AQUACULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AQUACULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CATTLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CATTLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CATTLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CATTLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CATTLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POULTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POULTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POULTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POULTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POULTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SWINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SWINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SWINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SWINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SWINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED ADDITIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED ADDITIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED ADDITIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED ADDITIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED ADDITIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED ADDITIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY IN OVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY IN OVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY IN OVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY IN OVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY IN OVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY IN OVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY WATER SOLUBLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY WATER SOLUBLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY WATER SOLUBLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY WATER SOLUBLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY WATER SOLUBLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY WATER SOLUBLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BOLUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BOLUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BOLUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BOLUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BOLUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BOLUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY LIQUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY LIQUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY LIQUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY LIQUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POWDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POWDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POWDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POWDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POWDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PREMIX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PREMIX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PREMIX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PREMIX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PREMIX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PREMIX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED MILLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED MILLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED MILLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED MILLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED MILLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED MILLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL ANIM